Beijing’s Bioyong Technology will collaborate with Biodesix of Boulder, Colorado to bring Biodesix’s VeriStrat® proteomic IVD to China. Using a blood sample, the VeriStrat test provides a prognosis for patients with non-small cell lung cancer, predicting the aggressiveness of the disease based on the host’s response to the tumor. Biodesix will receive about $38 million over the course of the collaboration. The two companies may also develop additional oncology tests and expand the use of VeriStrat into other Asia-Pacific countries.
